Chicago, ILNCT06912087Now EnrollingIRB Ready

Head and Neck Neoplasms Clinical Trial in Chicago, IL

Access cutting-edge head and neck neoplasms treatment through this phase 1 clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.

Sponsored by University of Chicago

Quick Self-Assessment

See if you qualify for this Chicago location

Preparing your pre-screening questions…

Expert Care in Chicago

Access head and neck neoplasms specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related head and neck neoplasms treatment provided free

Apply for This Chicago Location

Check if you qualify for this head and neck neoplasms clinical trial in Chicago, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chicago

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chicago site if eligible
  4. 4Begin participation

About This Head and Neck Neoplasms Study in Chicago

This Phase I clinical trial evaluates the safety, tolerability, and optimal dosing of Zanzalintinib in combination with Pembrolizumab and Cetuximab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC). The study aims to establish the maximally tolerated dose (MTD) and recommended Phase II dose (RP2D) while also exploring efficacy outcomes, including progression-free survival (PFS) and overall survival (OS).

Sponsor: University of Chicago

Who Can Participate

Inclusion Criteria

Histologically or cytologically confirmed recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC), which is considered incurable by local therapies.
Primary tumor locations: oropharynx, oral cavity, hypopharynx, larynx, nasopharynx, and sinonasal. Unknown primary is also eligible.
Age: Participants must be at least 18 years old.
ECOG Performance Status: Must be 0-1.
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.
For oropharyngeal cancer: HPV (p16) testing is required. p16 Immunohistochemistry (IHC) is sufficient for Human Papillomavirus (HPV) testing.
Programmed cell death ligand 1 (PD-L1) combined positive score (CPS) : For patients with previously untreated R/M disease, a combined positive score (CPS) of 1 or greater is required. There is no PD-L1 restriction for patients who have previously received anti-PD(L)1 therapy.
Recovery to baseline or ≤ Grade 1 severity (CTCAE v5) from any adverse events (AEs), including immune-related AEs from prior treatments.
Adequate organ and marrow function, including:
Absolute neutrophil count (ANC) ≥ 1500/mm3.
Platelets ≥ 100,000/mm3.
Hemoglobin ≥ 9 g/dL.
Normal liver and kidney function.
Capable of understanding and complying with the protocol requirements and must have signed the informed consent document.
Contraception: Sexually active fertile subjects must agree to use a highly effective method of contraception during the study and for 2 months after the last dose of cetuximab and 4 months after the last dose of pembrolizumab.

Exclusion Criteria

Prior treatment with Zanzalintinib or other vascular endothelial growth factor receptor (VEGFR)-targeted therapies, -Cetuximab, or other epidermal growth factor receptor (EGFR) inhibitors.
More than two prior lines of systemic therapy in the recurrent/metastatic setting.
Relapsed disease within 3 months of definitive therapy.
Prior treatment with small molecule kinase inhibitors, chemotherapy, biologic, or other anticancer therapies within certain time frames (2-4 weeks before the first dose of study treatment).
Brain metastases or cranial epidural disease unless stable after treatment for at least 4 weeks.
Concomitant anticoagulation with oral anticoagulants or platelet inhibitors, unless on stable doses of acceptable anticoagulants.
Active infection requiring systemic treatment or significant cardiovascular, gastrointestinal, or other serious health issues that may affect study participation.
Known or suspected autoimmune disease, except for specific conditions like type I diabetes or controlled skin disorders.
Pregnancy or breastfeeding: Women must not be pregnant or breastfeeding at screening.
Other malignancies within the past 2 years (except for certain low-grade cancers like localized skin cancers).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chicago?

Yes, this clinical trial (NCT06912087) has an active research site in Chicago, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Head and Neck Neoplasms Treatment Options in Chicago, IL

If you're searching for head and neck neoplasms treatment options in Chicago, IL, this clinical trial (NCT06912087) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chicago research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced head and neck neoplasms specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all head and neck neoplasms clinical trials near you to find additional studies recruiting in your area.

More Alzheimers Disease Trials in Chicago, IL

See all alzheimers disease clinical trials recruiting in Chicago — not just this study.

Browse Alzheimers Disease Trials in Chicago →

Browse More Trials by Condition

Alzheimers Disease TrialsMultiple Sclerosis TrialsAnkylosing Spondylitis TrialsAtopic Dermatitis TrialsAll Conditions →

Ready to Join in Chicago?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chicago, IL